EUVIMEDEUVIMED entdecken
Crossref

Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment

M Cuenin, J Salleron, D Peiffert, É Meknaci, P Gallet, Y Abushama, J-F Py, S Renard

Cancer/Radiothérapie · 2024

DOI: 10.1016/j.canrad.2023.06.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer/Radiothérapie, 2024. Verfasst von M Cuenin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy, France. Electronic address: m.cuenin@nancy.unicancer.fr. Hauptthemen laut MEDLINE: Brachytherapy, Mucositis, Carcinoma, Squamous Cell, Head and Neck Neoplasms. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy are known to be effective in the treatment of lip carcinomas. The aim of this study was to retrospectively compare oncologic and toxicity outcomes between the two techniques. PATIENTS AND METHODS: From 2007 to 2018, patients at the Institut de cancérologie de Lorraine (France) who received exclusive or adjuvant interstitial brachytherapy for lip squamous carcinomas were studied. Two groups were defined: the LDR/PDR group, including patients treated with iridium-192 wires, or pulsed-dose rate technique, and the high-dose-rate group, with patients treated by high-dose-rate technique. The dose ranged between 50Gy and 65Gy (depending on previous surgery) for low-dose-/pulsed-dose rate treatments, and 39Gy for high-dose-rate (twice a day). Early, late toxicity events and oncologic control were reported. RESULTS: Among the 61 patients whose data were analyzed retrospectively, 36 received the low-dose-/pulsed-dose rate treatment (59%) and 25 the high-dose-rate brachytherapy (41%). The median follow-up time was 44 months. At 36 months, the local control rates were 96.3% for LDR/PDR group and 100% for HDR (P=0.180). The regional control rates were 85.9% and 92% without any difference according to the two groups (P=0.179). The specific overall survival rate was 95.5% with no difference between groups. There were more grade 2 or higher mucositis in the HDR group than in LDR/PDR group (40% versus 16.7%, P=0.042). One case of grade 3 mucositis was recorded in each group. No grade 3 late complications were recorded. High-dose-rate brachytherapy reduced the length of hospitalization by 2 days (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyMucositisCarcinoma, Squamous CellHead and Neck NeoplasmsHumansRadiotherapy DosageIridium RadioisotopesRetrospective StudiesLip

Stichwörter der Autor:innen

Bas débit de doseBrachytherapyCarcinome des lèvresContrôle localCuriethérapieHaut débit de doseHigh-dose-rateLip carcinomaLocal controlLow-dose-rate

Substanzen

Iridium-192Iridium Radioisotopes

Autor:innen und Institutionen

  • Radiation Oncology Department, Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy, France. Electronic address: m.cuenin@nancy.unicancer.fr.
  • Biostatistics Department, Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.
  • Radiation Oncology Department, Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.
  • Head and Neck Surgery Department, CHU de Nancy, Nancy, France.

Zitieren

APA

Cuenin, M., Salleron, J., Peiffert, D., Meknaci, É., Gallet, P., Abushama, Y., Py, J. F., & Renard, S. (2024). Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2023.06.031

Vancouver

Cuenin M, Salleron J, Peiffert D, Meknaci É, Gallet P, Abushama Y, et al. Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment. Cancer/Radiothérapie. 2024. doi:10.1016/j.canrad.2023.06.031

BibTeX
@article{Cuenin2024,
  author = {Cuenin, M and Salleron, J and Peiffert, D and Meknaci, É and Gallet, P and Abushama, Y and Py, J-F and Renard, S},
  title = {Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment},
  journal = {Cancer/Radiothérapie},
  year = {2024},
  doi = {10.1016/j.canrad.2023.06.031}
}
Kostenlos starten →